Literature DB >> 8146858

Large-scale oligonucleotide typing for HLA-DRB1/3/4 and HLA-DQB1 is highly accurate, specific, and reliable.

J Ng1, C K Hurley, L A Baxter-Lowe, M Chopek, P A Coppo, J Hegland, D KuKuruga, D Monos, G Rosner, B Schmeckpeper.   

Abstract

DNA typing of HLA class II alleles of the DRB1/3/4 and DQB1 loci using sequence-specific oligonucleotide probes and polymerase chain reaction-amplified DNA was used for the large-scale typing of donors for the National Marrow Donor Program unrelated donor registry. The results of quality control analysis for the first 7 months of the project show the typing to be highly accurate, specific, and reliable. The percent of correctly classified HLA oligotypes based on 1652 DRB1 and 1652 DQB1 assignments was greater than 99% for DRB1/DRB3/DRB4 and greater than 98% for DQB1. This level of accuracy is particularly remarkable because the quality control samples could not be distinguished from 9011 donor samples tested at the same time by the laboratories.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8146858     DOI: 10.1111/j.1399-0039.1993.tb02191.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  8 in total

1.  Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk.

Authors:  P A Zimmerman; A Buckler-White; G Alkhatib; T Spalding; J Kubofcik; C Combadiere; D Weissman; O Cohen; A Rubbert; G Lam; M Vaccarezza; P E Kennedy; V Kumaraswami; J V Giorgi; R Detels; J Hunter; M Chopek; E A Berger; A S Fauci; T B Nutman; P M Murphy
Journal:  Mol Med       Date:  1997-01       Impact factor: 6.354

2.  Rheumatoid arthritis in the Women's Health Initiative: methods and baseline evaluation.

Authors:  Lewis H Kuller; Rachel H Mackey; Brian T Walitt; Kevin D Deane; V Michael Holers; William H Robinson; Jeremy Sokolove; Yuefang Chang; Larry W Moreland
Journal:  Am J Epidemiol       Date:  2014-02-24       Impact factor: 4.897

3.  Rheumatoid Arthritis, Anti-Cyclic Citrullinated Peptide Positivity, and Cardiovascular Disease Risk in the Women's Health Initiative.

Authors:  Rachel H Mackey; Lewis H Kuller; Kevin D Deane; Brian T Walitt; Yue-Fang Chang; V Michael Holers; William H Robinson; Russell P Tracy; Mark A Hlatky; Charles B Eaton; Simin Liu; Matthew S Freiberg; Mehret Birru Talabi; Erik B Schelbert; Larry W Moreland
Journal:  Arthritis Rheumatol       Date:  2015-09       Impact factor: 10.995

4.  Comparison of methods for in-house screening of HLA-B*57:01 to prevent abacavir hypersensitivity in HIV-1 care.

Authors:  Ward De Spiegelaere; Jan Philippé; Karen Vervisch; Chris Verhofstede; Eva Malatinkova; Maja Kiselinova; Wim Trypsteen; Pawel Bonczkowski; Dirk Vogelaers; Steven Callens; Jean Ruelle; Kabamba Kabeya; Stephane De Wit; Petra Van Acker; Vicky Van Sandt; Marie-Paule Emonds; Paul Coucke; Erica Sermijn; Linos Vandekerckhove
Journal:  PLoS One       Date:  2015-04-15       Impact factor: 3.240

5.  The Pharmacogenomic HLA Biomarker Associated to Adverse Abacavir Reactions: Comparative Analysis of Different Genotyping Methods.

Authors:  Laura Stocchi; Raffaella Cascella; Stefania Zampatti; Antonella Pirazzoli; Giuseppe Novelli; Emiliano Giardina
Journal:  Curr Genomics       Date:  2012-06       Impact factor: 2.236

6.  Clustering and alignment of polymorphic sequences for HLA-DRB1 genotyping.

Authors:  Steven Ringquist; Gaia Bellone; Ying Lu; Kathryn Roeder; Massimo Trucco
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

7.  Measuring ambiguity in HLA typing methods.

Authors:  Vanja Paunić; Loren Gragert; Abeer Madbouly; John Freeman; Martin Maiers
Journal:  PLoS One       Date:  2012-08-29       Impact factor: 3.240

Review 8.  HLA Association with Drug-Induced Adverse Reactions.

Authors:  Wen-Lang Fan; Meng-Shin Shiao; Rosaline Chung-Yee Hui; Shih-Chi Su; Chuang-Wei Wang; Ya-Ching Chang; Wen-Hung Chung
Journal:  J Immunol Res       Date:  2017-11-23       Impact factor: 4.818

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.